ECONOMIC IMPACT OF PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER
Author(s)
Mulani P1, Botteman M2, Hay JW3, Cifaldi M11 Abbott Laboratories, Abbott Park, IL, USA; 2 PharMerit North America, Bethesda, MD, USA; 3 University of Southern California, Los Angeles, CA, USA
OBJECTIVE: There is limited information about cost implications of prostate-specific antigen doubling time (PSADT) in patients with hormone-refractory prostate cancer (HRPCA). This research was undertaken to assess the association between PSADT four-months. Costs were broken down by service type; management, surgery, ancillary, facility and pharmacy. The costs of HRPCA patients with PSADT four-months . In addition, a within-group analysis compared the cost of patients with PSADT
Conference/Value in Health Info
2005-05, ISPOR 2005, Washington, DC, USA
Value in Health, Vol. 8, No. 3 (May/June 2005)
Code
PCN10
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Oncology